Catalyst Wire Dossier Catalyst Wire Dossier

Aybintio

bevacizumab · Samsung Bioepis NL B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Aybintio, covering 2026-01-28 to 2026-01-28. Get the full timeline:

Most recent: EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.

See pricing